Results 51 to 60 of about 66,662 (177)

Application of sirolimus in an infant presenting with a life-threatening lymphatic malformation of the head and neck: a case report

Frontiers in Pediatrics
Extensive lymphatic malformations in the head and neck region pose a significant risk due to potential airway compression, and conventional treatment modalities have proven largely ineffective.
Shuying Yu, Xiaowen Guo
doaj   +1 more source

Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process

International Journal of Nanomedicine, 2011
Min-Soo Kim1, Jeong-Soo Kim1, Hee Jun Park1, Won Kyung Cho1,3, Kwang-Ho Cha1,3, Sung-Joo Hwang2,31College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea, 2College of Pharmacy, 3Yonsei Institute of Pharmaceutical Sciences, Yonsei ...
Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ   +5 more
doaj  

Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges

Neuroprotection, EarlyView.
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi, Mohammadreza Salehi, Razieh Mohammad Jafari, Ramin Goudarzi, Saman Khosravi, Ahmad Reza Dehpour   +5 more
wiley   +1 more source

Sirolimus for the treatment of Graves’ orbitopathy

Thyroid Research
Objectives A role of mTOR (mammalian target of rapamycin) in the pathogenesis of Graves’ Orbitopathy (GO) has been proposed and rapamycin, better known as sirolimus, an mTOR inhibitor, was recently used in patients with GO.
Simone Comi, Elena Sabini, Giada Cosentino, Ferruccio Santini, Michele Marinò   +4 more
doaj   +1 more source

Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial

Journal of Immunology Research, 2019
Background. We have reported previously the insufficient absolute number or functional defects of regulatory T cells (Tregs) in patients with rheumatoid arthritis (RA), challenging conventional unspecific immunosuppressive therapy.
Hong-Yan Wen, Jia Wang, Sheng-Xiao Zhang, Jing Luo, Xiang-Cong Zhao, Chen Zhang, Cai-Hong Wang, Fang-Yuan Hu, Xiao-Juan Zheng, Ting Cheng, Hong-Qing Niu, Guang-Ying Liu, Wen-Xian Yang, Na-Na Yu, Jin-Li Ru, Qi-Xiang Chen, Xue-Chun Lu, Pei-Feng He, Chong Gao, Xiao-Feng Li   +19 more
doaj   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

Internal Medicine Journal, EarlyView.
Abstract Background Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
Andrea Henden, Lynette Chee, Julia Clark, Rachel Conyers, Julian Cooney, Richard Doocey, David Gottlieb, Tim Prestidge, Madeleine Powys, Philip Selby, Gaurav Sutrave, Eric Wong, Michelle K. Yong, Nada Hamad   +13 more
wiley   +1 more source

The Economic Consequences of Sirolimus Treatment in Patients With Vascular Malformations

Journal of Vascular Anomalies
Objectives:. Sirolimus is one of the first oral drugs for safe and effective treatment of patients with vascular malformations, and may save (expensive) interventions.
Veroniek E. M. Harbers, Wietske Kievit, Raquel Duque Jimenez, Leo J. Schultze Kool, Ingrid M. P. van Rijnsoever, Bas H. Verhoeven, Carine J. M. van der Vleuten, D. Maroeska W. M. te Loo, Members of the Vascular Anomalies Working Group (VASCA WG) of the European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN)—Project ID: 769036   +8 more
doaj   +1 more source